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ABSTRACT
Expression of imprinted genes is classically asso-
ciated with differential methylation of specific CpG-
rich DNA regions (DMRs). The H19/IGF2 locus is
considered a paradigm for epigenetic regulation. In
mice, as in humans, the essential H19 DMR—target
of the CTCF insulator—is located between the two
genes. Here, we performed a pyrosequencing-based
quantitative analysis of its CpG methylation in
normal human tissues. The quantitative analysis of
the methylation level in the H19 DMR revealed three
unexpected discrete, individual-specific methylation
states. This epigenetic polymorphism was confined
to the sixth CTCF binding site while a unique
median-methylated profile was found at the third
CTCF binding site as well as in the H19 promoter.
Monoallelic expression of H19 and IGF2 was main-
tained independently of the methylation status at
the sixth CTCF binding site and the IGF2 DMR2
displayed a median-methylated profile in all indi-
viduals and tissues analyzed. Interestingly, the
methylation profile was genetically transmitted.
Transgenerational inheritance of the H19 methyla-
tion profile was compatible with a simple model
involving one gene with three alleles. The existence
of three individual-specific epigenotypes in the
H19 DMR in a non-pathological situation means it
is important to reconsider the diagnostic value
and functional importance of the sixth CTCF
binding site.
INTRODUCTION
Imprinted genes are expressed from only one of the parental
chromosomes (1,2). Generally they are located in clusters and
epigenetically marked by DNA methylation, histone
acetylation/deacetylation and histone methylation and often
associated with antisense RNAs (3,4). In mice, extensive
studies of the paradigmatic imprinted H19/Igf2 region
revealed that the physical contacts between differentially
methylated regions (DMRs), containing insulators, silencers
and activators, lead to transcriptional regulation of both
H19 and Igf2 genes (5,6). Methylation of the paternally
derived allele at an imprinting control region (ICR) located
2 kb upstream of H19 (H19 DMR) is required to silence
H19 and to activate Igf2 on the chromosome of paternal ori-
gin. Reciprocally, absence of methylation on the maternal
allele in the H19 DMR leads to expression of the maternal
H19 allele and the silencing of Igf2 throughout development
(7). Mechanistically, the H19 DMR is the biological target for
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doi:10.1093/nar/gkl657CTCF, a zinc ﬁnger CCCTC-binding factor, which can bind
to four sites on the unmethylated maternal H19 DMR (8,9).
The binding of CTCF creates a physical boundary on the
maternal allele and inhibits interaction of downstream
enhancers with Igf2 promoters (10). In addition, CTCF bind-
ing to H19 DMR might be necessary to prevent de novo
methylation of the maternal allele (11).
Comparative analysis of a paternal-speciﬁc methylation
imprint at the human H19 locus revealed the presence of
several highly similar 400 bp repeats containing CpG islands,
although no signiﬁcant sequence homology to the corre-
sponding region of the mouse H19 DMR could be identiﬁed
(12). Much less is known about the functional regulation
in humans compared to mice. The human H19 DMR encom-
passes seven different binding sites for CTCF. Only the sixth
CTCF binding site has been reported to act as a key regula-
tory domain for switching between H19 and IGF2 expression,
whereas the other sites appear to be hyper-methylated in a
study by Takai et al. (13). Anomalies in methylation patterns
of the H19/IGF2 locus have been consistently proposed as
epigenetic markers of human disease (14–18).
However, the correlation between H19 DMR methylation
and expression is not always strictly deﬁned. In normal
human brain, biallelic expression of IGF2 and/or H19 is
found despite differential methylation and CTCF binding
(19). Also an inter-individual variability in IGF2 imprinting
with biallelic expression has been observed in lymphocytes
of  10% of normal individuals (20). In addition, a familial
aggregation of ‘abnormal methylation’ in  7% of analyzed
samples was identiﬁed at the sixth CTCF binding site (21).
These studies suggest overall that the regulation of methyl-
ation near imprinted genes might be leakier in human
compared to mice.
Imprinted genes are probably the most important buffering
factors for regulating the day-to-day trades between mother
and foetus in placental mammals. Therefore understanding
their regulation is of particular importance for understanding
human placental physiopathology. Expression and gene
invalidation data demonstrate the great importance of the
H19/IGF2 locus in placental development and physiology
(22–24). Both genes are expressed at very high levels and
with high speciﬁcity in human placenta (25). In this tissue,
the analysis of the H19 DMR methylation proﬁle yielded con-
trasting results, with either an early monoallelic expression of
H19 established as soon as the ﬁrst trimester (8–12 weeks)
(26) or a progressive acquisition of monoallelic expression
between the ﬁrst trimester and normal term ( 39 weeks)
(27). This discrepancy between the methylation of H19
DMR and expression of H19/IGF2, raises the general ques-
tion of the correlation and anteriority between DNA methyl-
ation, histone modiﬁcation, and the ultimate mark of
imprinting, monoallelic expression.
Due to the high expression of both genes in placenta and its
importance in placental development, we chose to analyze
systematically methylation patterns at the sixth CTCF bind-
ing site in DNAs extracted from placentas of two develop-
mental stages in a normal population. We further analyzed
lymphocyte DNA as a second tissue to identify tissue-speciﬁc
effects. DNA methylation patterns are mainly investigated
by cloning and subsequent sequencing, a time consuming
process restricting the number of analyzed molecules to the
order of tens. Recently, the pyrosequencing technology was
developed and validated for DNA methylation analysis of
numerous individual samples providing excellent quantitative
resolution (28–30).
In this study we demonstrate the existence of three
individual-speciﬁc methylation proﬁles in human lymphocyte
DNA as well as in placenta at the sixth CTCF binding site.
This observation, although not correlated with a loss of mono-
allelic expression of H19 and IGF2 raises important questions
about the functional importance of the sixth CTCF binding
site in humans as well as its implication in regulation at
this locus. Furthermore, we can show that the three levels
of methylation could be explained by a genetic model invol-
ving a unique effecting locus. This represents the ﬁrst exam-
ple of transgenerational heritability of DNA methylation
levels in a human non-pathological situation. Finally, these
results further challenge the diagnostic value of methylation
proﬁles in the H19/IGF2 imprinting control region as a
marker for cancer or epigenetic diseases such as the
Beckwith–Wiedemann or Silver–Russell syndrome.
MATERIALS AND METHODS
Sample collection
Sample collection (blood, placental villi and spermatozoa
samples) was performed under a protocol approved by the
institutional ethics committee. No individual identiﬁers or
history, other than lack of known malformations were
recorded. Informed consent was obtained from all individuals
for the use of samples of placenta, blood and spermatozoa.
Fifteen early term (between 8 and 14 weeks of amenorrhoea)
and 40 full term placentas (37–40 weeks of amenorrhea) were
analyzed. In 29 cases, the placenta-maternal blood sample
pair was collected. In 10 cases, the placenta-cord blood and
maternal blood samples were collected. Blood DNA samples
from 37 individuals from 6 two- to four- generation families
and from a second independent cohort of 19 adult patients
were collected and analyzed. DNAs of 30 individuals from
8 families extracted from lymphoblastoid cell lines of the
CEPH/Utah collection were obtained from the DNA banking
facility of the CNG (Evry, France). In addition, spermatozoa
from 10 normozoospermic individuals were collected.
Nucleic acid isolation
Genomic DNA was isolated from adult lymphocytes, from
dissected and washed placental villi and from spermatozoa
by incubation with proteinase K (0.2 mg/ml) in Lysis Saline
Buffer following standard methods. RNA extraction was per-
formed from placental villi using Trizol reagent (Invitrogen
Life Technology, Cergy, France).
Methylation assays
The bisulphite conversions of genomic DNA (1 mg) and
pyrosequencing analysis were performed as previously
described (29,30). Supplementary Table 1 lists the accession
numbers and nucleotide positions of the analyzed regions, the
PCR primers and annealing temperatures used, the size of
the PCR products and the number of CpGs analyzed. Primers
for PCR ampliﬁcation, pyrosequencing and primer extension
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Brieﬂy, 50 ng of bisulphite converted DNA was added as
template into PCR buffer with 1 mM MgCl2, 200 mM
dNTP, 0.4 mM of each forward and reverse biotinylated pri-
mer and 2.0 U Platinium Taq polymerase (Invitrogen Life
Technology). The PCR program consisted of a denaturing
step of 4 min at 95 C followed by 50 cycles of 30 s at
95 C, 30 s at the hybridization temperature (see Supplemen-
tary Table 1) and 20 s at 72 C, with a ﬁnal extension of 5 min
at 72 C. Puriﬁcation of the PCR product with streptavidin
Sepharose  HP beads (GE Healthcare, Uppsala, Sweden)
and hybridization of the biotinylated PCR products and
the sequencing primer were conducted following the PSQ96
sample preparation guide using a vacuum ﬁltration sample
transfer device (Pyrosequencing AB, Uppsala, Sweden).
Sequencing was performed on a PSQ 96MA system with
the PyroGold SQA reagent kit according to the manufac-
turer’s instructions (Pyrosequencing AB). All PCRs were
checked for the absence of preferential ampliﬁcation by
mixing known ratios of whole-genome ampliﬁed and
in vitro methylated (SssI, Ozyme, St Quentin-en-Yvelines,
France) DNA. Pyrosequencing primers and templates were
controlled for self-extension or primer-dimer formation.
The veriﬁcation of the methylation status of selected CpG
positions was performed by MALDI mass spectrometry as
previously described (29,31). For cloning and sequencing,
the PCR products were subcloned into a TA cloning vector
(pGemT vector, Promega, Charbonnieres, France) according
to manufacturer’s instructions and 30 clones were selected
for sequencing.
Allele-specific expression
Allele-speciﬁc expression was carried out by genotyping of
the RsaI polymorphism (rs3741219) in exon 5 of H19 and
the ApaI polymorphism (rs680) in exon 9 of IGF2, respec-
tively. RT–PCR products were analyzed for samples hetero-
zygous for the respective SNPs (n ¼ 34 for H19 and
n ¼ 10 for IGF2, respectively). Primers are listed in Supple-
mentary Table 2. After the cDNA synthesis, PCR products
were either analyzed by standard Sanger sequencing on a
3730 ABI sequencer using the above described primer set
(rs3741219, rs2839704 and rs2839703) for the H19 gene, or
digested by ApaI and electrophoresed on a 2% agarose gel to
analyze the IGF2 polymorphism.
Quantitative RT–PCR
Real-time PCR was performed using a Lightcycler (Roche
TM
Diagnostics, Mannheim, Germany) and SYBR Green master
mix (Invitrogen) to quantify gene expression. Primers (Sup-
plementary Table 2) were designed to amplify a region
encompassing exons 7, 8 and 9 of IGF2 and a region in
exon 5 of H19. Relative expression of IGF2 and H19
is shown normalized to the expression of the succinate
dehydrogenase A (SDHA).
Genotyping of polymorphisms
Genomic DNA was analyzed for two SNPs (rs10732516 and
rs 2071094) and RT-PCR products were analyzed for three
SNP (rs2839703, rs2839704 and rs3741219). Genotyping of
polymorphisms were performed by pyrosequencing using
the SNP genotyping kit according to the manufacturer’s
instructions (Pyrosequencing AB).
Statistical analysis
A Mann–Whitney rank test was used to determine whether
the epigenotypes (hypo-, median- and hyper-methylated
proﬁles) were associated with tissue type (placenta versus
lymphocytes) and to test the distribution of the H19 and
IGF2 expressions in early term and full-term placentas. A
Monte Carlo based permutation test was used to evaluate
the statistical signiﬁcance of the distribution of the methyla-
tion proﬁles to exclude random effects. Student’s t-test was
used to test the signiﬁcance of gene expression differences
between groups. A c
2 test was used to determine whether
the proportion of the different genotypes (CC, TT and CT,
SNP rs10732516) was similar in the general population and
in individuals analyzed in this study.
RESULTS
Methylation analysis of the sixth CTCF binding site in
the H19 DMR
We analyzed the methylation levels at sixteen consecutive
CpGs at the sixth CTCF binding site in the H19 DMR in
DNA from lymphocytes (maternal blood cells, blood 1) as
an adult control tissue, and in DNA from human placentas
at two different stages of placental development (early gesta-
tion, 8–14 weeks of amenorrhea, or at full term gestation,
37–40 weeks of amenorrhea) by pyrosequencing. While
an overall methylation level of 50% was expected, a high
variability of methylation levels between individuals and
consecutive CpGs was found leading to a surprisingly
complex methylation pattern in both adult lymphocytes and
placentas (Figure 1A–C). The ﬁfth CpG in the DMR was com-
pletely unmethylated for some samples, which is explained by
the existence of a C/T SNP (rs10732516). DNA samples har-
boring a T were therefore completely unmethylated, which
explains the dip in the methylation level at this position for
several of the DNA samples. This polymorphism did not affect
the global methylation level of the DMR. After exclusion of
the ﬁfth CpG the methylation proﬁles in the H19 DMR
could be grouped into three discrete methylation categories
in maternal blood cell DNA (Figure 1A): a hyper-methylated
proﬁle (average methylation > 66%: 80.2 ± 8.2%), a median-
methylated proﬁle (33% < average methylation < 66%:
44.5 ± 5.1%) and a hypo-methylated proﬁle (average methyl-
ation < 33%: 17.7 ± 7.5%). The median-methylated proﬁle
was encountered in 59% of the lymphocyte samples, while
the hypo- and hyper-methylated represented 28% and 13%,
respectively. A Monte-Carlo based permutation test (n ¼
5000) was used to test objectively for this discrete distribution
into three categories (from 0 to 33%, from 33 to 66% and from
66 to 100% of methylation, respectively). Compared with the
simulated dataset, probabilities of P < 0.008, P < 0.002 and
P < 0.03 were obtained for the three categories, respectively.
It can thus be concluded that the repartition was non-random
and results from genuine biological differences. To exclude
any sampling bias, we conﬁrmed the distribution of the
methylation status in a second independent cohort of nineteen
adult individuals (Figure 1D, blood 2).
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restricted to lymphocyte DNA. Similar proﬁles were also
observed in placental tissue DNA (Figure 1B and C), albeit
with a less clear division between the hypo- and median-
methylated proﬁles, consistent with the classical observation
of a placental hypo-methylation compared to other tissues.
The frequencies of the three epigenotypes were not different
between the two independent cohorts of lymphocyte DNAs
(maternal or from anonymous adult individuals), early term
or full term placentas (Figure 1D). Also inside each methyla-
tion group the inter-individual variations were not signiﬁ-
cantly different between placenta and lymphocyte samples.
The parental origin of the methylated strands was
addressed by cloning and Sanger sequencing of PCR products
from three placental samples corresponding to each one of the
three different methylation proﬁles and heterozygous for
the single nucleotide polymorphism rs2071094 (Figure 2).
The hyper-methylated proﬁle corresponds mainly to methy-
lated DNA molecules from both the maternal and paternal
origin. Similarly, the hypo-methylated proﬁle corresponded
mainly to unmethylated molecules from both parental alleles.
Consistent with the classical model, the median-methylated
proﬁle corresponded to the presence of methylated molecules
of paternal origin.
Validation of the epigenetic profiles at the sixth CTCF
binding site
Since our results were unexpected and somewhat contradic-
tory to published observations of the homologous mouse
DMR, we controlled and reproduced the results to exclude
any technical artefacts in addition to the cloning and sequenc-
ing experiment described above.
(i) To rule out incomplete bisulphite conversion of the
genomic DNA, the bisulphite treatments were standar-
dized and verified. Systematically, 1 mg of genomic
DNA was used for bisulphite conversion and 50 ng of
converted DNA for PCR amplification. Conversion rates
were confirmed by cloning and sequencing PCR
products. This revealed that >99% of unmethylated
cytosines were converted. Four independent replicates of
the bisulphite treatment followed by PCR amplification
were carried out for six placental DNA samples,
displaying a very good reproducibility of the process
(SD < 5.0%; Supplementary Figure 1A). The same
methylation profiles were obtained using a second
primer set encompassing the previous primer positions
(n ¼ 6, Supplementary Figure 1B).
(ii) Since the structure of the H19 DMR is very complex and
consists of highly similar repeats (12), the specificity of
the amplified PCR products was checked by system-
atically reanalyzing the amplified sequence at each base
pair to demonstrate that the DMR encompassing the
sixth CTCF binding site was exclusively amplified.
Supplementary Figure 2 shows the alignment of the
different consecutive binding sites proving that the sixth
CTCF site is clearly distinguishable from the others after
pyrosequencing. Any additional or missing base in the
analyzed sequence—even partially—would induce
Figure 1. Profiles of H19 DMR methylation obtained by pyrosequencing in maternal lymphocyte DNA samples (A, Blood 1, n ¼ 29) and in placenta DNA
samples at early term (B, ETP, n ¼ 15) and full term of gestation (C, FTP, n ¼ 40 analyzed; n ¼ 20 represented). A similar distribution was found in placenta and
the two cohorts of lymphocytes (Blood 1 and Blood 2, D). The fifth CpG analyzed corresponds to a C/T polymorphic position in the CTCF binding site
(rs10732516).
Nucleic Acids Research, 2006, Vol. 34, No. 19 5441failure of the pyrosequencing procedure, which is based
on the sequential input of the correct nucleotides into the
elongating DNA strand.
(iii) Results were further confirmed by an independent
quantitative method using a single base primer extension
assay combined with MALDI mass spectrometric detec-
tion for several CpG inside the analyzed DMR (31).
The methylation level of the H19 DMR is
individual-speciﬁc but does not depend
on the tissue analyzed
We analyzed DNAs originating from the placenta and
from blood of the foetus, taken at the time of birth for
10 individuals. The methylation proﬁle was found to be
identical in the two different tissues from the same individual
(Figure 3). This showed that the epigenotype (hypo-, median-
or hyper-methylated) is acquired early in development,
probably before the separation of the syncytiotrophoblast
from the inner cell mass. This early determination supports
a strict determinism of the methylation status, which is
maintained through the individual’s life.
Familial transmission of H19 DMR epigenotypes
The literature evoked the existence of ‘aberrant’ familial
aggregation of methylation at the sixth CTCF binding
site (21). Since different epigenotypes were often observed
Figure 2. Cloning and Sanger sequencing of PCR products from three placental samples corresponding to the three different profiles. SNP rs2071094 was used to
determine the parent-of-origin of the methylated alleles.
Figure 3. Methylation profiles at the sixth CTCF binding site in placental (closed squares) and foetal lymphocyte DNA (closed triangles) samples in comparison
to the maternal lymphocyte DNA samples (open triangle) for three different mother-child pairs.
5442 Nucleic Acids Research, 2006, Vol. 34, No. 19in the analysis of the mother/placenta pairs, we envisaged that
these different epigenotypes could be due to familial segrega-
tion of ‘methylated’ alleles. Therefore we tested the possibi-
lity of genetic transmission of the three observed methylation
levels. We analyzed the epigenetic proﬁles of 6 two- to four-
generation families encompassing a total of 37 children
(Figure 4, only the four most informative families are presen-
ted), as well as the epigenotypes of 29 mother/placenta pairs.
When considering the transmission pattern from parents
(both sexes) to children, 83 transmissions could be followed,
which were 9 hypo-, 52 median- and 22 hyper-methylated.
In a random situation, the epigenotype of the descendant
would not be inﬂuenced by the epigenotype of the parent.
Under this hypothesis, for a given child epigenotype, the
probability of each parent epigenotype is 1/3. In fact, the
actual proportions varied according to each epigenotype.
These proportions were tested by a c
2 test and were found
to be highly signiﬁcant (P ¼ 0.00014). This indicated that
the transmission from parent to child was not random. In
addition, we tested the epigenotypes of lymphocytes from
48 unrelated individuals (blood 1 and blood 2 cohorts), yield-
ing 27, 59 and 14% of hypo-, median- and hyper-methylated
epigenotypes, respectively. This sample was used as a refer-
ence population. These proportions were markedly different
from that observed in our six families (P ¼ 0.0006). These
data showing different proportions in familial structures
compared to a cohort of unrelated individuals strengthen
the hypothesis of a genetic transmission of the epigenotypes.
Without exception, our familial transmission patterns were
compatible with a model of a single gene presenting three
alleles and a strict model of dominance: median- > hypo- >
hyper-methylated. The model was compatible with
Hardy–Weinberg equilibrium.
In order to further validate the likelihood of our model we
tried to follow methylation proﬁles in families from the
CEPH-Utah collection analysing 30 different individuals
from 8 families. However, all samples displayed a median-
methylated proﬁle with an average methylation of 38%.
This homogeneity has probably been acquired during
immortalization of the cells or cell culture.
To test for a correlation between the genetic structure
of the locus and the methylation proﬁle we compared geno-
type data from haplotype-tagging SNPs in the DMR upstream
of H19, in H19 itself and in IGF2 (J. Tost, unpublished
data) to the epigenetic proﬁle, but no association was
found. In DNA from puriﬁed spermatozoa, the analysis of
the H19 DMR methylation proﬁle by pyrosequencing
showed complete hyper-methylation, as expected for sperma-
tozoa (n ¼ 10). This suggests that the individual-speciﬁc
methylation status of H19 DMR observed in lymphocytes
and in placentas is acquired after fertilization during the
differentiation of somatic cell lineages.
Spatial extension of the three methylation profiles
Methylation profiles are restricted to the sixth CTCF site.
To determine the extent of the variable epigenetic proﬁles,
we analyzed 10 CpGs encompassing the third CTCF site
(Figure 5) as well as 9 CpGs in the direct proximal promoter
region of H19. All samples displayed  40% methylation at
these two loci.
Methylation status of IGF2 DMR2 is independent of the
epigenotype at the sixth CTCF site in the H19 DMR. In mice,
the H19 DMR is needed on the maternal allele to protect the
Igf2 DMR1 and 2 from methylation (7). To assess a putative
link of the methylation level at the sixth CTCF site of the
H19 DMR with the methylation level in the IGF2 DMR2
we analyzed the methylation status of the IGF2 DMR2
by pyrosequencing. Two regions encompassing 17 CpGs
(278 bp, IGF2 DMR2a) and 9 CpGs (195 bp, IGF2
DMR2b), separated by 265 bp and located in exons 8 and
9o fIGF2 (Figure 6) were quantitatively screened for
individual-speciﬁc differential methylation. A highly speciﬁc
and reproducible proﬁle was observed for the DMR, irrespec-
tive of the sample used (placentas or maternal blood cells).
Strong variability of methylation was observed between con-
secutive CpGs. The average proportion of methylated mole-
cules in the ﬁrst region (IGF2 DMR2a) was 62.9 ± 7.3% in
lymphocytes (maternal blood cells, MBC), 47.5 ± 4.9% in
early gestation placenta (ETP) and 41.1 ± 5.4% in term placenta
Figure 4. Familial segregation of individuals with various methylation profiles analyzing DNA samples from fresh blood.
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lower than in adult lymphocytes (P < 0.0001). Similarly, the
IGF2 DMR2b was hypo-methylated in placenta samples:
35.0 ± 8.9% in ETP, 34.0 ± 3.6% in FTP and 57.4 ± 3.9%
in maternal blood cells, respectively (Figure 6). Again the dif-
ference between [FTP-ETP] and MBC methylation levels was
highly signiﬁcant (P < 0.0001). By contrast, the methylation
status of both DMR2a and 2b were never signiﬁcantly
different between early gestation and full term placentas.
The comparative analysis of the H19 and IGF2 DMRs from
the same samples revealed that their methylation levels were
not correlated in humans.
Relationship between H19 DMR epigenotypes and
expression of both H19 and IGF2 genes in human
placenta
We then addressed the question whether the epigenetic poly-
morphism (three proﬁles) at the sixth CTCF binding site had
an effect on the allele-speciﬁc expression of either H19 or
IGF2 as well as on the quantity of the mRNA of both
genes. As H19 and IGF2 are highly expressed in placenta
but not in lymphocytes, 34 placental DNA, heterozygous
for the SNP rs3741219 (RsaI cleavage site) in the last exon
of H19, were selected (Supplementary Table 3). These sam-
ples were used to follow H19 allelic expression by RT–PCR
followed by conventional Sanger sequencing. A single allele
was exclusively expressed in 25 cDNA samples (83.3%) and
predominantly expressed in ﬁve cDNA samples (16.7%). In
this case, 80% of the cDNA molecules originated from one
allele and 20% from the second. There was no correlation
with the methylation proﬁle of the corresponding genomic
DNA samples (among the three samples where H19 was
not exclusively expressed from the maternal allele, one was
hyper-, one was hypo-, and one was median-methylated).
Similarly, samples informative (n ¼ 10) for the ApaI
polymorphism in exon 9 of IGF2 demonstrated the allele-
speciﬁc expression of the gene without exception. Therefore,
the imprinting status of both genes is maintained whatever the
methylation proﬁle of the sixth CTCF binding site.
We measured the overall expression levels of IGF2 and
H19 in early gestation and full-term placental villi by quanti-
tative RT–PCR. A very strong positive correlation was found
between the IGF2 and H19 mRNA levels in ETP (R
2 ¼ 0.87)
and a less strong in FTP (R
2 ¼ 0.36, Figure 7). Very clearly,
both genes are expressed at a much lower level at full-term
compared to early gestation placentas (Mann–Whitney test:
P ¼ 0.008). Finally, the overall level of H19 and IGF2
expression was analyzed with regard to the methylation pro-
ﬁle of the H19 DMR, but no signiﬁcant differences could be
found. In conclusion our results dissociate the methylation
status of the sixth CTCF site of the H19 DMR from the
expression level of both H19 and IGF2 and suggest that
other complementary mechanisms could be at work for
maintaining a speciﬁc expression level of both genes in the
placenta.
DISCUSSION
This sixth CTCF site has previously been postulated as being
the only one of the seven CTCF sites that is used for imprint-
ing control (13). Therefore, the sixth CTCF binding site
might be considered as the human functional homologue of
the allele-speciﬁcally methylated region in the mouse H19/
IGF2 ICR despite low sequence conservation between the
two species. Our study shows that the sixth CTCF binding
site is not consistently allele-speciﬁcally methylated in
humans. However, the expected median-methylated pattern
is found in another region of the DMR, as well as in the
H19 promoter. Our observations suggest that the sixth
CTCF binding site is at least not always involved in the
allele-speciﬁc expression of H19 and IGF2 and that either
Figure 5. DNA methylation profiles of the third CTCF binding site obtained by pyrosequencing. The degree of methylation (%) was analyzed for 11 CpGs.
Analysis was performed on the same samples as for the IGF2 DMR2 (Figure 6). A unique profile was obtained. Only 14 samples are shown for clarity.
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lation state of the locus determines imprinted expression.
Alternatively, species-speciﬁc mechanisms might exist in
the onset and/or maintenance of imprinting in different mam-
mals. In addition, we found that the methylation proﬁle for a
given individual is determined early in development (before
the division of the inner cell mass lineage and the trophecto-
derm lineage) and presumably genetically determined.
DNA methylation is generally addressed by cloning and
DNA sequencing of PCR products from bisulphite treated
DNA. This has become the standard technique for determin-
ing the methylation status of CpG imprinted regions. The
major limitation of this technique is that it extrapolates
methylation data from a reduced number of independently
sequenced DNA molecules (generally 10–20) to a whole tis-
sue. DNA methylation analysis by pyrosequencing has
become more and more widespread as it combines important
features such as ease-of-use, quantitative accuracy and high-
throughput possibilities. For the presented study, the use of
pyrosequencing also minimized the risk of technical artifacts.
The sequences of the different CTCF sites are very similar,
but do differ at some nucleotides. Any unspeciﬁc ampliﬁca-
tion of, e.g. several binding sites, would therefore be seen
in the resulting pyrogram and would not pass quality control.
Two recent studies demonstrated the presence of microdele-
tions fusing different CTCF binding sites in the H19 DMR
Figure 6. Profiles of IGF2 DMR methylation obtained by pyrosequencing. The degree of methylation (%) was analyzed for two differentially methylated
regions, 17 CpGs in DMR2a and 9 CpGs in DMR2b. Analysis was performed on maternal blood cell DNA samples (A, Blood 1 n ¼ 17), on placenta samples at
early term of gestation (B, n ¼ 6) and at full term (C, n ¼ 16).
Nucleic Acids Research, 2006, Vol. 34, No. 19 5445that lead to the hyper-methylation at the sixth CTCF binding
site in Beckwith–Wiedemann syndrome patients (32,33).
Although we can not exclude microdeletions in other parts
of the DMR, we can be sure that the results are not due to
a deletion or fusion of CTCF sites as this would, for the
above described reasons, be visible in the obtained sequences.
As the same methylation proﬁle is found in different tissues
from the same individual (blood and placenta), any artifact
in the preparation of the DNA from the placentas and the
lymphocytes can clearly be ruled out.
When analyzing the four functional CTCF sites in mice in
ten different organs by pyrosequencing, we found a unique
methylation proﬁle in all organs as well as in the different
analyzed mice (J. Tost, unpublished data). In humans, previ-
ous work showed that paternal speciﬁc methylation at H19
DMR is very well conserved not only in tissues that have par-
ental speciﬁc expression of the two genes, but also in tissues
such as the choroid plexus where expression is biallelic (34).
Our results show that the opposite situation exists, i.e. tissues
where the typical imprinted pattern of expression does not
directly correlate with speciﬁc methylation levels. Indeed,
while a major part of the human population exhibited the
expected allele-speciﬁc methylation pattern, 34 to 65%, of
the human population escapes the classically described
median-methylated proﬁle of the DMR (34% in maternal
lymphocytes, 43% when considering male and female adult
lymphocytes, 65% in placentas).
Aberrant methylation in the H19 DMR has previously been
reported, mainly in analyses in the context of cancer. For
example Cui et al. reported hyper-methylation at the ﬁrst
CTCF site in Wilms tumour with loss of imprinting, but
also Wilms tumour samples with normal imprinting of
IGF2 did not necessarily show a normal pattern of methyla-
tion at the H19 DMR. A recent study on head and neck car-
cinomas showed aberrant hyper-methylation at the sixth
CTCF binding site in the control population (35). While
Takai et al. (13) only found allele-speciﬁc methylation at
the sixth CTCF binding site when analysing a few normal tis-
sues, Sandovici et al. (21) reported on a familial aggregation
of ’aberrant’ methylation in a non-pathological situation. Our
results support the ﬁndings reported by Sandovici et al. (21)
which observed a sporadic or familial abnormal methylation
status of H19 DMR as well as stability of this trait over a
period of nearly two decades. However, due to the method
based on methylation sensitive restriction endonucleases
used in that study, they were only able to detect hyper- and
median-methylated samples and therefore did not understand
the full extent of the epigenetic polymorphism. By their
method, a hypo-methylated proﬁle is indistinguishable
from the expected median-methylated methylation level as
in both cases one allele is retrieved after digestion. Only a
complete loss of methylation would result in a different
result. This would also explain their higher percentage of
median-methylated samples as they would have classed all
but the hyper-methylated samples in this category. Their
reported observations were also consistent with the possibility
that a H19 DMR epigenotype is largely due to genetic factors.
Germline transmitted epimutations has been found in
several plants and two metastable transposon-associated
epimutations were described in mice (36). The maternally
transmitted epigenetic state of the Agouti viable yellow allele
determines coat color (37) and a parent-of-origin independent
transmission of differential methylation at an internal retro-
transposon of the Axin
Fu allele leads to a presence or absence
of the phenotype, a kinked tail (38). The only previously
reported transgenerational inherited human epiallele concerns
the mutL homolog 1 (MLH1) where methylated alleles confer
an increased risk to develop cancer (39,40). We have shown
that the observed epigenetic proﬁles at the sixth CTCF bind-
ing site are non-random and follow a pattern of inheritance
that might be determined by a single genetic factor. Further
work on familial genotyped DNAs from non-immortalized
cell lines will be necessary to map the putative locus or
gene responsible for the three methylation proﬁles and
ascertain the proposed model of dominance.
Our ﬁndings suggest the absence of a direct connection
between H19 monoallelic expression and H19 DMR allele-
speciﬁc methylation at the sixth CTCF binding site. Allele-
speciﬁc methylation at this locus might therefore play only
a secondary role as an epigenetic mark in humans. Alterna-
tively, it could be a primary mark early in development,
which is then lost after the blastocyst stage. A contrasted situ-
ation was found in mice with respect to the imprinting centre
located in the Kcnq1 domain on distal chromosome 7. In the
embryo, imprinting is stably maintained only on genes that
have promoter DNA methylation whereas in the placenta,
the paternal repression along this domain involves the
acquisition of histone H3 methylation without the involve-
ment of promoter DNA methylation (41,42).
The correlation between the total expression levels of
IGF2 and H19 suggests a co-regulation by a process acting
simultaneously on the two homologous chromosomes and
equilibrating the amount of transcript of both genes at speciﬁc
stages of developing placenta. This could for example be
achieved by a limiting amount of transcription factor. This
hypothesis is strengthened by a systematic bioinformatic
analysis of promoters from the H19/IGF2 locus demonstra-
ting that the transcription factor binding site content of the
P3 of IGF2 is highly similar to that of the P1 of H19
(D. Vaiman et al., unpublished data).
In conclusion, we could demonstrate the existence of three
distinct non-random individual-speciﬁc methylation levels at
the sixth CTCF site in the H19 DMR, which are probably
set by a so far unidentiﬁed genetic factor. An immediate
consequence of our study is the need for re-consideration of
Figure 7. H19 and IGF2 expression levels in human placenta. Real-time
quantitative PCR was performed using cDNA from 6 early- and 10 full-term
placentas, respectively. Succinate dehydrogenase A (SDHA) gene expression
was used as standard.
5446 Nucleic Acids Research, 2006, Vol. 34, No. 19methylation of at least the sixth CTCF site as diagnostic mar-
ker for cancer or epigenetic ‘diseases’ such as Silver–Russel
and Beckwith–Wiedemann syndrome.
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